Otsuka Holdings Co ( (OTSKF) ) has released its Q3 earnings. Here is a breakdown of the information Otsuka Holdings Co presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Otsuka Holdings Co., Ltd. is a diversified healthcare company based in Japan, operating in the pharmaceutical, nutraceutical, consumer products, and other sectors, with a focus on enhancing well-being through innovative products and services.
In its latest earnings report for the nine-month period ending September 30, 2025, Otsuka Holdings reported a steady increase in revenue and profits, driven by strong performance in its pharmaceutical and nutraceutical segments. The company’s revenue rose by 5.1% to ¥1,818,743 million, while operating profit surged by 56.1% to ¥407,421 million, reflecting significant growth in its core products and strategic investments.
Key highlights include a notable increase in sales of antipsychotic agent REXULTI/RXULTI and anti-cancer agent LONSURF, alongside growth in the nutraceutical business, particularly in the ‘For Women’s Health’ and ‘For Healthier Life’ categories. The company’s operating profit benefited from gains associated with the sale of shares in MicroPort Scientific Corporation, despite some impairment losses.
Looking ahead, Otsuka Holdings remains optimistic about its financial outlook, with expectations of continued revenue growth in the pharmaceutical and nutraceutical sectors. The company plans to maintain its focus on strategic investments and cost management to support sustainable growth and enhance shareholder value.